BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 34485812)

  • 1. Management of Cancer-Associated Thrombosis: Unmet Needs and Future Perspectives.
    Falanga A; Gal GL; Carrier M; Abdel-Razeq H; Ay C; Martin AJM; Rocha ATC; Agnelli G; Elalamy I; Brenner B
    TH Open; 2021 Jul; 5(3):e376-e386. PubMed ID: 34485812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants.
    Vedovati MC; Giustozzi M; Becattini C
    Thromb Res; 2019 May; 177():33-41. PubMed ID: 30849513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.
    Kirkilesis GI; Kakkos SK; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2019 May; 57(5):685-701. PubMed ID: 31097186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis.
    Al-Samkari H; Connors JM
    Cancers (Basel); 2018 Aug; 10(8):. PubMed ID: 30111746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
    O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE
    Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism.
    Giustozzi M; Franco L; Vedovati MC; Becattini C; Agnelli G
    J Thromb Thrombolysis; 2019 Oct; 48(3):439-453. PubMed ID: 31104194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of cancer-associated venous thromboembolism - a case-based practical approach.
    Voigtlaender M; Langer F
    Vasa; 2018 Feb; 47(2):77-89. PubMed ID: 29325495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges.
    Frere C; Benzidia I; Marjanovic Z; Farge D
    Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30634638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venous thromboembolism prophylaxis in medically ill patients: a mixed treatment comparison meta-analysis.
    Al Yami MS; Silva MA; Donovan JL; Kanaan AO
    J Thromb Thrombolysis; 2018 Jan; 45(1):36-47. PubMed ID: 29043538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
    Marik PE; Cavallazzi R
    PLoS One; 2015; 10(11):e0143252. PubMed ID: 26587983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies.
    Swartz AW; Drappatz J
    Oncologist; 2021 May; 26(5):427-432. PubMed ID: 33523555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
    Pernod G; Joly M; Sonnet B
    J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.
    Ay C; Beyer-Westendorf J; Pabinger I
    Ann Oncol; 2019 Jun; 30(6):897-907. PubMed ID: 30918939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of venous thromboembolism in patients with cancer: from clinical trials to real life.
    Verso M; Agnelli G
    Thromb Res; 2020 Jul; 191 Suppl 1():S123-S127. PubMed ID: 32736770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis.
    Vedovati MC; Giustozzi M; Bonitta G; Agnelli G; Becattini C
    Thromb Res; 2018 Oct; 170():175-180. PubMed ID: 30196195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of venous thromboembolism in patients with cancer with direct oral anticoagulants: A systematic review and meta-analysis.
    Chen H; Tao R; Zhao H; Jiang J; Yang J
    Medicine (Baltimore); 2020 Jan; 99(5):e19000. PubMed ID: 32000440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis.
    Alhousani M; Malik SU; Abu-Hashyeh A; Poznanski NJ; Al-Hasan S; Roth DF; Alsharedi M; Mustafa B
    Thromb Res; 2021 Feb; 198():103-114. PubMed ID: 33310644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
    Wu C; Alotaibi GS; Alsaleh K; Linkins LA; McMurtry MS
    Thromb Res; 2015 Feb; 135(2):243-8. PubMed ID: 25488466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far?
    Voigtlaender M; Langer F
    Hamostaseologie; 2017 Oct; 37(4):241-255. PubMed ID: 28508916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of cancer associated thrombosis: Which role for direct oral anticoagulants in 2018?].
    Frère C; Farge D
    J Med Vasc; 2018 Sep; 43(5):293-301. PubMed ID: 30217343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.